Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin PK with Rifampicin in Advanced Solid Tumors
NCT03002493Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in solid tumor (advanced stage), sponsored by Eisai Co., Ltd. Primary endpoints: Best overall tumor response up to 8 months, Area under the concentration-time curve from zero extrapolated to infinite time at Day 15 and 6 more. Started Dec 2009; status: completed.
02
Drugs
eribulin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03002493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002493.